The first non-surgical repair for Pelvic Organ Prolapsebroad
apyx · Horizon Europe grant · 2023-10-01–2025-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
Pelvic Organ Prolapse (POP) affects nearly 50% of women over 40 years old globally. 89% of the cases seek treatment for symptomatic early stage prolapse. Despite the high prevalence and the progression of POP over time, patients currently cannot be offered a repair solution until the condition worsens enough for surgical intervention. However, the surgical interventions of prolapse have several side effects like prolonged recovery, pelvic pain and relapses of POP. Escala Medical has developed a minimally invasive and incision-free repair intervention for early-stage POP repair - Apyx. Apyx is the first medical device for treating early stage prolapse, regaining quality of life and prevention of prolapse deterioration for the vast majority, currently un-addressed, POP sufferers. The EIC project will finalize the development of Apyx, conduct clinical trials, and support scale-up and commercialization activities.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| ESCALA MEDICAL LTD | IL | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.